← Leaderboards
Jianying Zhang
University Of Texas El Paso
$4,093,961
Attributed
$4,093,961
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $586K · FY2007–23$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,093,961 · 3
By mechanism
U54$2,626,800 · 1
SC1$1,022,954 · 1
S06$444,207 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas El Paso
Same institution · by research overlap
- Eva Margarita Moya$1,629,668
- Rosa A Maldonado$4,365,494
- Joseph Tomaka$299,000
- Thenral Mangadu$963,733
- Edward M Heath$996,626
Others in their field
Top investigators on “Malignant Neoplasm Of Liver”
- David Heimbrook · Leidos Biomedical Research, Inc.$177,665,368
- Richard Douglas Moore · Johns Hopkins University$35,618,815
- Paul M. Ridker · Brigham And Women'S Hospital$34,275,148
- Larry Arthur$32,456,757
- Charles R Rinaldo · University Of Pittsburgh At Pittsburgh$31,582,503
- Mardge H Cohen · Hektoen Institute For Medical Research$29,891,507
Research focus
Malignant Neoplasm Of LiverMalignant NeoplasmsTissuesProteomicsDesignBaseTherapeutic InterventionEarly DiagnosisTissue SampleSamplingCancer PatientDiagnosticMolecularTexasUniversitiesClinical TrialsCohortAntibodiesBiomedical ResearchCollaborationsDetectionCharacteristicsAntineoplastic AgentsCause Of Death
Grant awards (14)
Developing Diagnostic and Therapeutic Strategies to Reduce Hispanic Cancer Disparities Using Genetic, Molecular and Physiological Signatures from Mexican origin Cancer Patients$515,166
U54 · FY2023 · MD · contact PI
Developing Diagnostic and Therapeutic Strategies to Reduce Hispanic Cancer Disparities Using Genetic, Molecular and Physiological Signatures from Mexican origin Cancer Patients$499,296
U54 · FY2022 · MD · contact PI
Developing Diagnostic and Therapeutic Strategies to Reduce Hispanic Cancer Disparities Using Genetic, Molecular and Physiological Signatures from Mexican origin Cancer Patients$25,332
U54 · FY2022 · MD · contact PI
Developing Diagnostic and Therapeutic Strategies to Reduce Hispanic Cancer Disparities Using Genetic, Molecular and Physiological Signatures from Mexican origin Cancer Patients$490,360
U54 · FY2021 · MD · contact PI
Developing Diagnostic and Therapeutic Strategies to Reduce Hispanic Cancer Disparities Using Genetic, Molecular and Physiological Signatures from Mexican origin Cancer Patients$510,610
U54 · FY2020 · MD · contact PI
Developing Diagnostic and Therapeutic Strategies to Reduce Hispanic Cancer Disparities Using Genetic, Molecular and Physiological Signatures from Mexican origin Cancer Patients$586,036
U54 · FY2019 · MD · contact PI
Autoantibodies to tumor-associated antigens as diagnostic biomarkers in liver can$253,776
SC1 · FY2014 · CA · contact PI
Autoantibodies to tumor-associated antigens as diagnostic biomarkers in liver can$245,928
SC1 · FY2013 · CA · contact PI
Autoantibodies to tumor-associated antigens as diagnostic biomarkers in liver can$261,625
SC1 · FY2012 · CA · contact PI
Autoantibodies to tumor-associated antigens as diagnostic biomarkers in liver can$261,625
SC1 · FY2011 · CA · contact PI
Identifying Tumor-Associated Antigens for Detection of Hepatocellular Carcinoma$108,398
S06 · FY2010 · GM · contact PI
Identifying Tumor-Associated Antigens for Detection of Hepatocellular Carcinoma$122,857
S06 · FY2009 · GM · contact PI
Identifying Tumor-Associated Antigens for Detection of Hepatocellular Carcinoma$94,190
S06 · FY2008 · GM · contact PI
Identifying Tumor-Associated Antigens for Detection of Hepatocellular Carcinoma$118,762
S06 · FY2007 · GM · contact PI